Oneness Biotech Company Description

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products primarily in Taiwan.

It offers Fespixon cream for diabetic foot ulcers. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials.

It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis; OB318, an anticancer botanical drug of antrodia cinnamomea; SNS812, for the treatment of COVID-19 that is in Phase II clinical trials; and SNS851 for weight loss and metabolism diseases.

In addition, the company engages in the management of agriculture cultivation and trading business; and production and sale of agricultural products.

Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.

Oneness Biotech Co., Ltd.

Country	Taiwan
Founded	2008
Industry	Biotechnology
Sector	Healthcare
Employees	43
CEO	Shuling Cheng

Contact Details

Address: No. 66, Zhonzheng W. Rd. Taipei, 100 Taiwan
Phone	886 2 2703 1098
Website	onenessbio.com

Stock Details

Ticker Symbol	4743
Exchange	Taipei Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0004743000
SIC Code	2836

Key Executives

Name	Position
Nien-Yi Chen	Deputy General Manager of Antibody New Drug Division;
Dr. Shuling Cheng Ph.D.	President
Ting-Fang Chen	Financial Officer and Acting Spokesperson
Ai-Chia Yu	Accounting Officer
Wen Ci Xiao	Accounting Supervisor
Dr. Jui-Ching Chen Ph.D.	Director of New Drug Development Department
Kung-Ming Lu	Director of Operation Center
Tzu-Chun Yang	Associate General Manager of Information Technology Department